Drug Helps Prevent Hip Fractures In Parkinson Disease

Main Category: Parkinson's Disease
Also Included In: Bones / Orthopedics;  Neurology / Neuroscience;  Clinical Trials / Drug Trials
Article Date: 22 Mar 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 and a half stars

4.5 (4 votes)

Healthcare Prof:3 stars

3 (2 votes)


A drug used to strengthen bone has been found to help reduce the high incidence of hip fractures among people with Parkinson disease, according to a study published in the March 20, 2007, issue of Neurology®, the scientific journal of the American Academy of Neurology.

The two-year study involved 242 elderly men with Parkinson disease in Tokyo, Japan. Half of the group received the drug risedronate and vitamin D2. The remaining men received placebo and vitamin D2.

The study found the men taking risedronate were three times less likely to sustain a hip fracture compared to the placebo group.

Researchers also found bone mineral density (BMD) among men taking risedronate increased by 2.2 percent and decreased by nearly three percent in the placebo group. In addition, researchers found a biomarker for bone loss decreased by nearly 47 percent in the risedronate group and 33 percent in the placebo group.

"Prior to the study, these men had been experiencing a rapid rate of bone loss due to inactivity. Our findings show risedronate, along with vitamin D2, effectively controls the progression of osteoporosis, and reduces the risk of hip fractures," said study author Yoshihiro Sato, MD, with Mitate Hospital in Tokyo.

Sato says the findings also show risedronate is stronger than the drug alendronate, which has been found in previous studies to reduce bone loss and prevent hip fractures in elderly women with Parkinson disease.

Side effects of risedronate included inflammation of the esophagus and abdominal pain, which eventually healed with appropriate therapy, according to the study.

The study was supported by Takeda Pharmaceuticals, which helped develop risedronate.

The American Academy of Neurology, an association of more than 20,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson's disease, and multiple sclerosis.

For more information about the American Academy of Neurology, visit http://www.aan.com.

American Academy of Neurology (AAN)
1080 Montreal Ave.
St. Paul, MN 55116
United States
http://www.neurology.org

Article adapted by Medical News Today from original press release.
Visit our parkinson's disease section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Christian Backing. "Drug Helps Prevent Hip Fractures In Parkinson Disease." Medical News Today. MediLexicon, Intl., 22 Mar. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/65775.php>

APA
Christian Backing. (2007, March 22). "Drug Helps Prevent Hip Fractures In Parkinson Disease." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/65775.php.

Please note: If no author information is provided, the source is cited instead.


Parkinson's Disease

What is Parkinson's Disease?

Parkinson's disease is a gradually progressive, degenerative neurologic disorder which typically impairs the patient's motor skills, speech, writing, as well as some other functions. Read more...

Most Popular Articles



Follow Our Parkinson's Disease News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Parkinson's Disease Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »